The Covid-19 pandemic shifted the economy in many ways. Some industries and practices became nearly obsolete. Other industries have seen exponential growth....
The article MAPS Completes Second Phase 3 MDMA Trial was originally published on Microdose. MAPS PBC Completes Second Phase 3 “MAPP2” Trial of...
The article Predicting Psychedelic Outcomes was originally published on Microdose. One of the hardest parts about taking psychedelics is entering the...
The results of the company’s Phase 2b trial raise concerns around safety, efficacy, and money, suggesting key questions to be addressed in Phase 3. The...
Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelics-based therapeutics,...
The article Field Trip Announces New Ketamine Therapy Program: Freedom by Field Trip™ was originally published on Microdose. Field Trip Announces the...
The psychedelics research company ended the quarter with less than $100K cash. The post Mydecine Continues Cash Burn through Q3 appeared first on Green...
There is a high rate of adverse physical effects and challenging psychological effects from using the plant-based psychoactive ayahuasca, though they are...
You may have never heard of psilacetin. In fact, when you first saw it, it may have confused you. “Is this a misspelling of psilocybin? Is...
ReMind Psychedelics Business Forum was held Nov. 15 in Las Vegas. The post A Psychedelics Forum: How the Industry is Evolving into Tomorrow appeared first...